In Taiwan’s regulatory framework, a biologic refers to a product derived from living organisms, such as proteins, vaccines, blood products, or monoclonal antibodies. These products are more complex than chemical drugs and require stringent clinical and quality data, including immunogenicity assessments and Good Manufacturing Practice (GMP) compliance, for TFDA approval.
